Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Melanoma 26Neuroblastoma 25Breast Neoplasms 20Prostatic Neoplasms 18Leukemia 15Multiple Myeloma 14Lymphoma 14Leukemia, Myeloid, Acute 14Glioblastoma 14Lymphoma, Non-Hodgkin 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Leukemia, Lymphocytic, Chronic, B-Cell 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms, Male 8Myelodysplastic Syndromes 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Glioma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Fallopian Tube Neoplasms 6Osteosarcoma 5Hodgkin Disease 5Carcinoma, Renal Cell 5Brain Neoplasms 5Uveal Melanoma 4Recurrence 4Rectal Neoplasms 4Medulloblastoma 4

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gliosarcoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01480479 2018-01-16

ACT IV

Celldex Therapeutics

Phase 3 Completed
745 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡